SEC Comment Letter 0000000000-26-003024 to Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc.
Date: March 25, 2026 · CIK: 0001774857 · Accession: 0000000000-26-003024
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294537
Letter
Re: Aardvark Therapeutics, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294537 Dear Tien-Li Lee, M.D.:
March 25, 2026
Tien-Li Lee, M.D. Chief Executive Officer Aardvark Therapeutics, Inc. 4370 La Jolla Village Drive, Suite 1050 San Diego, CA 92122
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Samantha H. Eldredge, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 25, 2026 Tien-Li Lee, M.D. Chief Executive Officer Aardvark Therapeutics, Inc. 4370 La Jolla Village Drive, Suite 1050 San Diego, CA 92122 Re: Aardvark Therapeutics, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294537 Dear Tien-Li Lee, M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Samantha H. Eldredge, Esq. </TEXT> </DOCUMENT>